Approvals, filings, CRLs, breakthrough designations and advisory committees.
The UK's MHRA has authorised Onswik (insulin efsitora alfa) for adults with type 2 diabetes. The drug is given once weekly, which for some patients can reduce annual injections from up to 365 to 52.
Why it matters: Once-weekly dosing cuts annual injections from up to 365 to 52, letting readers compare adherence with current basal insulin regimens.
The FDA has approved two new blood tests to detect Alzheimer disease in adults with cognitive symptoms, one of which is indicated for people as young as 40. The source is an RSS summary only; product names and further details of the two tests are not provided.
Why it matters: Two Alzheimer blood tests were approved, one for people as young as 40, a useful comparison with the indicated populations of earlier blood tests.
The FDA has approved a first-in-class therapy for patients with metastatic pancreatic cancer. The original brief gives no drug name, mechanism of action, or trial data; consult the original article for details.
Why it matters: Heat: 2 sources reported the same event
China's National Medical Products Administration has approved the registration of a transcatheter pulmonary valve system developed by Beijing Balance Medical Technology as an innovative medical device. The system, comprising a delivery system with a deliverer and loader, uses a mini-thoracotomy approach and is indicated for patients aged at least 9 years and weighing at least 20 kg with severe pulmonary regurgitation and a native right ventricular outflow tract after surgery for complex congenital heart disease.
Why it matters: NMPA approval of a novel transcatheter pulmonary valve device adds a new option for post-surgical congenital heart disease patients.
On September 29, 2026, the NMPA approved the breast cancer indication for paclitaxel oral solution (brand name Bairuisu), a product of 3SBio and Shanghai Haihe Pharmaceutical, for recurrent or metastatic HER2-negative breast cancer. The drug, the first oral paclitaxel formulation worldwide, was previously approved in September 2024 as second-line treatment for advanced gastric cancer. Its use now extends from gastric to breast cancer, offering an oral option for a chemotherapy long given only by injection.
Why it matters: First oral paclitaxel gains a second approved indication, expanding home-based chemotherapy to breast cancer.
China's NMPA has approved the marketing application for Foresee Pharmaceuticals' Camcevi 42 mg for advanced prostate cancer in adults. The drug is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate. GenSci holds exclusive commercialization rights in China, covering central precocious puberty, premenopausal breast cancer, and advanced prostate cancer.
Why it matters: China's NMPA approved Camcevi 42 mg for adult advanced prostate cancer.
The US FDA has approved Hovilpri (pritelivir), an oral herpes simplex virus (HSV) drug from Japan's Asahi Kasei, as the first HSV treatment with a new mechanism of action approved in nearly 30 years. The drug is the core asset from Asahi Kasei's $920 million acquisition of German biotech Aicuris in April 2026.
Why it matters: First new-mechanism HSV approval in nearly 30 years, from a recent $920 million acquisition.
Revolution Medicines' pan-RAS inhibitor Rasonque (daraxonrasib) received FDA approval in August for metastatic pancreatic ductal adenocarcinoma, making it the first RAS-class drug for this indication.
Why it matters: The article contrasts the first pan-RAS inhibitor Rasonque with existing KRAS G12C inhibitors, helping readers place it within RAS-pathway therapies.
The FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen), the first disease-modifying drug for Alexander disease, a rare progressive and often fatal neurological condition affecting about one person per 1-3 million. The antisense oligonucleotide targets RNA encoding glial fibrillary acidic protein (GFAP), reducing its overproduction in astrocytes, where excess GFAP forms clumps that disrupt myelination. Patients suffer impaired motor function, seizures, intellectual disability and developmental delays.
Why it matters: First disease-modifying therapy approved for a rare, previously untreatable neurological condition.
The FDA approved Weltruza, a once-monthly subcutaneous olanzapine long-acting injectable, on 2026-10-09 for psychotic disorders. It was developed by Teva with Medincell's SteadyTeq technology and supported by the SOLARIS trial (NCT05693935). Unlike olanzapine's existing LAI, it requires no loading dose, oral overlap or post-injection monitoring; psychiatrists discussing it flagged cost and insurance coverage as open questions.
Why it matters: Clinicians see it as an adherence-friendly alternative to current LAIs, with cost and sedation still unresolved.
Teva announced FDA approval of Weltruza, a once-monthly subcutaneous long-acting injectable olanzapine for schizophrenia. Approval was based on Phase III SOLARIS trial data (NCT05693935). Weltruza uses Medincell copolymer sustained-release technology and comes in 318mg, 425mg and 531mg doses corresponding to oral 10mg, 15mg and 20mg, with no loading dose, oral supplementation or post-injection monitoring required. It launches in the US within weeks.
Why it matters: Approved on Phase III SOLARIS data, monthly dosing without loading doses or post-injection monitoring offers an alternative for patients with poor long-term adherence.
The US FDA has approved Asahi Kasei Therapeutics' Hovilpri (pritelivir) 100mg tablets for refractory mucocutaneous HSV lesions in immunocompromised adults who do not respond to standard antiviral treatments such as acyclovir, famciclovir, or valacyclovir.
Why it matters: The article gives specific day-28 and day-42 complete healing and safety differences, and compares Hovilpri's helicase-primase mechanism with nucleoside analogues.
China's NMPA has approved a new indication for Daiichi Sankyo (China)'s datopotamab deruxtecan injection, for adults with unresectable or metastatic triple-negative breast cancer who are not suitable for PD-1/PD-L1 inhibitor therapy. The approval, shown on the NMPA website on October 8, 2026, was detailed in a Daiichi Sankyo press release. Triple-negative breast cancer accounts for about 10%-15% of all breast cancers and is aggressive with high recurrence and poor prognosis.
Why it matters: Regulatory approval of a new indication for an imported original drug in a hard-to-treat breast cancer setting.
The FDA has approved the first HSV treatment with a new mechanism of action in nearly 30 years, an oral antiviral drug. It offers a new option for high-risk patients whose HSV infections have failed standard antiviral therapy, a heavy burden particularly among immunocompromised populations.
Why it matters: First new-mechanism HSV drug approved by FDA in nearly three decades addresses unmet need in treatment-refractory patients.
China's National Medical Products Administration has approved the innovative device registration application of Beijing Bairui Medical Technology's transcatheter pulmonary valve system, filed by Beijing Bairui Medical Technology Co., Ltd. The system, comprising a delivery system with a conveyor and a loader, is placed via a small transthoracic incision. It is indicated for patients aged 9 or older weighing at least 20 kg with severe pulmonary regurgitation and a native right ventricular outflow tract after surgery for complex congenital heart disease.
Why it matters: NMPA approval of a novel transcatheter pulmonary valve adds a minimally invasive option for post-surgical congenital heart disease patients.
The FDA approved Teva's WELTRUZA (olanzapine extended-release injectable suspension) on October 9, 2026 for adults with schizophrenia. It is the first once-monthly subcutaneous long-acting olanzapine approved worldwide, and unlike earlier long-acting olanzapine injections it requires no routine 3-hour post-injection observation and no supplemental oral olanzapine at treatment start.
Why it matters: First-approved monthly subcutaneous long-acting olanzapine removes monitoring and oral-loading burdens for schizophrenia patients.
The FDA approved Asahi Kasei's pritelivir (Hovilpri), a helicase-primase inhibitor, on 2026-10-09 for refractory HSV mucosal infections in immunocompromised adults, making it the first HSV drug with a new mechanism in nearly 30 years. Approval rests on the Phase 3 PRIOH-1 trial. Reddit users criticized accessibility, with one estimating roughly $26,667 per person for a 42-day course based on projected revenue of $400 million across 15,000 immunocompromised patients; no official price was given.
Why it matters: First new-mechanism HSV drug approval in nearly 30 years, with community-disputed cost estimates.
FDA has approved Hovilpri (pritelivir) tablets for mucocutaneous herpes simplex virus lesions in immunocompromised adults who did not respond to acyclovir, valacyclovir, or famciclovir.
Why it matters: Source gives 28-day healing rates of 63% versus 34% in controls, letting readers assess the benefit size.
China's NMPA approved datopotamab deruxtecan (Dato-DXd) on September 29, 2026 for adults with unresectable or metastatic triple-negative breast cancer who are not suitable for PD-1/PD-L1 inhibitor treatment. It is the first and only TROP2-targeting ADC approved for this indication with an overall survival benefit, and it marks Dato-DXd's second breast cancer approval in China after HR-positive, HER2-negative advanced breast cancer.
Why it matters: Approval expands Dato-DXd into a hard-to-treat mTNBC population lacking effective options.
The FDA has approved AbbVie's D1/D5 receptor partial agonist Juvmo (tavapadon) for the treatment of Parkinson's disease in adults. The approval adds a new option that works by selectively modulating D1/D5 receptors, a subclass of dopamine receptors identified as a potential Parkinson's target more than 30 years ago, though progress on the approach had been slow. Juvmo becomes a newly approved choice for adult patients.
Why it matters: First FDA approval of a D1/D5-selective mechanism in a target area stalled for over 30 years.
